| Trial ID # | NCT03029598 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Carboplatin, Pembrolizumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 27; median 5 prior therapies (2-9) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, OS, evaluated per RECIST |
| Biomarkers | Exploratory: PD-L1 status |
| Efficacy | ORR: 10.6% (3PR, n=29) 7 of 23 evaluable patients (30.4%) had archival tumor with modified percent scoring ≥5 for PD-L1 and all achieved PR (3/7, 42.8%) or SD (4/7, 57.2%) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Promising activity of pembrolizumab with low dose carboplatin in heavily pretreated patients |
| Reference | Liao JB et al. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. J Immunother Cancer (2021) 9(9):e003122 |